Home > Rheumatology > ACR 2021 > Spotlight on Rheumatoid Arthritis > Kidney disease and hydroxychloroquine dose are risk factors for developing retinopathy

Kidney disease and hydroxychloroquine dose are risk factors for developing retinopathy

Presented By
Dr April Jorge, Massachusetts General Hospital, MA, USA
Conference
ACR 2021
Long-term use and high-dose treatment were among the independent risk factors that distinctly augment the risk of retinopathy for patients with systemic lupus or other rheumatoid diseases treated with hydroxychloroquine. Another risk factor is comorbid chronic kidney disease, which nearly doubled the retinopathy risk. Previous findings suggested a 5 times higher risk for retinopathy in patients within the first 10 years of hydroxychloroquine treatment when treated with 5 mg/kg/day; thus, guidelines recommend to not pass this threshold [1,2]. To identify risk factors for hydroxychloroquine retinopathy, Dr April Jorge (Massachusetts General Hospital, MA, USA) and colleagues obtained data from the Kaiser Permanente Northern California consortium to ascertain a large cohort of 4,899 subjects with systemic lupus erythematosus or other rheumatoid diseases with incident hydroxychloroquine use of ≥5 years between 1997 and 2020 [3]. All participants had at ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on